Octapharma USA research at AAAAI: cutaquig® study at higher infusion rates presented
PARAMUS, N.J. (March 6, 2023) – Octapharma USA presented research at the American Academy of Allergy, Asthma & Immunology (AAAAI) ...
Tag: cutaquig
FDA approves Octapharma’s cutaquig® 16.5% for pediatric PI patients, providing flexible treatment options
Credit: Octapharma USA PARAMUS, N.J. (December 7, 2021) – Octapharma USA today announced the U.S. Food & Drug Administration (FDA) ...
-
UTHSC researchers’ work on human pangenome aids understanding of common chromosomal abnormality
-
Null results research now published by major behavioral medicine journal
-
Pediatric Cancer Research Foundation announces 2023 grant recipients to accelerate discovery of new treatments for pediatric cancers
-
For advanced, HER2-amplified bile duct cancers, antibody treatment trial shows promising results
-
Case report: former football player’s cognitive symptoms improved after study revealed alternative diagnosis and treatment
-
Multiple sclerosis more prevalent in Black Americans than previously thought